Indian company Zydus to present data on Lipaglyn in steatohepatitis

Indian pharma company Zydus is to present data from its Lipaglyn (saroglitazar) study at the 2015 Keystone Symposia Conference on Liver Metabolism and Non-alcoholic Fatty Liver Disease (NAFLD).

The drug has already demonstrated good efficacy data in animal models in the treatment of non-alcoholic steatohepatitis and associated biomarkers, reducing hepatic steatosis, ballooning, inflammation and fibrosis of the liver. The recently-completed Phase II studies in patients with biopsy-proven non-alcoholic fatty liver disease have shown improvement in liver enzymes and favorable effects on lipid and glycemic indices.

Pankaj Patel, chairman and managing director of Zydus Cadila, said: “There are currently no approved therapies to treat NASH. Saroglitazar is showing promise in NASH, and Zydus will continue further research to develop this important therapeutic for NASH patients.”